- Lifeist’s (LFST) U.S. biosciences subsidiary, Mikra Cellular Sciences, received its first purchase order from GNC for Mikra’s CELLF v1.2
- GNC is a leading global health and wellness brand that provides high-quality, science-based products and solutions to consumers
- CELLF v1.2 is a cellular health nutraceutical gel, formulated with bioactive compounds to positively impact brain, heart, skin and muscular systems
- Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness
- Lifeist Wellness Inc. (LFST) opened trading at C$0.04 per share
Lifeist’s (LFST) U.S. biosciences subsidiary, Mikra Cellular Sciences, received its first purchase order from GNC for Mikra’s CELLF v1.2.
GNC Holdings is a leading global health and wellness brand that provides high-quality, science-based products and solutions to consumers. It has over 4,000 retail locations across the United States and over 2,000 internationally. GNC is the largest global specialty retailer of nutritional products.
The company has signed a distribution agreement with GNC to make it the exclusive distribution partner for CELLF v1.2 and its future derivatives in the U.S.
About CELLF v1.2
CELLF v1.2 is a cellular health nutraceutical gel. It is engineered with a natural biological delivery system to pass through gastric environments unchanged and deliver directly to cells. It is formulated with bioactive compounds clinically studied in more than 145 human studies to positively impact brain, heart, skin and muscular systems.
CELLF v1.2 is currently available on Mikra’s proprietary e-commerce platform and on Amazon.com. CELLF v1.2 will also be available on GNC.com, GNC’s Amazon store and in select stores nationwide beginning June 2023.
About Lifeist Wellness
Lifeist leverages advancements in science and technology to build breakthrough companies that transform human wellness. Its portfolio business units include CannMart, CannMart Labs, Australian Vapes, and Mikra.
Lifeist Wellness Inc. (LFST) opened trading at C$0.04 per share.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
